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ASCORBATE DEPLETION INCREASES GROWTH AND METASTASIS 
OF MELANOMA CELLS IN VITAMIN C DEFICIENT MICE
J. Cha, M.W. Roomi, V. Ivanov, T. Kalinovsky, A. Niedzwiecki*, M. Rath
Dr. Rath Research Institute, Santa Clara, CA 95050
Aim: Our main objective was to determine the effect of ascorbate supplementation in mice unable to synthesize ascorbic acid 
(gulo KO) when challenged with murine B16FO cancer cells. Methods: Gulo KO female mice 36–40 weeks of age were deprived 
of or maintained on ascorbate in food and water for 4 weeks prior to subcutaneous injection of 2.5×106 B16FO murine mela-
noma cells in the right flank of mice. A control group of wild type mice were also injected with the melanoma cells and maintained 
on a regular murine diet. Mice were continued on their respective diets for another 2 weeks after injection. The mice were then 
sacrificed, blood was drawn and their tumors were measured, excised and processed for histology. Results: Mean weight of animals 
decreased significantly (30%, p < 0.0001) in the ascorbate-restricted group but increased slightly, but insignificantly, in the ascor-
bate-supplemented group. The mean tumor weight in ascorbate supplemented mice was significantly reduced (by 64%, p = 0.004) 
compared to tumor weight in ascorbate-deprived gulo mice. The mean tumor weight of wild type mice did not differ significantly 
from the ascorbate-supplemented mice. Gulo KO mice supplemented with ascorbate developed smaller tumors with more collagen 
encapsulation and fibrous capsule interdigitation, while gulo KO mice deprived of ascorbate hosted  large tumors with poorly de-
fined borders, showing more necrosis and mitosis. Ascorbate supplementation of gulo KO mice resulted in profoundly decreased 
serum inflammatory cytokine IL-6 (90% decrease, p = 0.04) and IL-1β (62% decrease) compared to the levels in gulo KO mice 
deprived of ascorbate. Conclusion: Ascorbate supplementation modulated tumor growth and inflammatory cytokine secretion as well 
as enhanced encapsulation of tumors in scorbutic mice. 
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Melanoma causes the majority of skin cancer-re-
lated deaths, due to metastasis to other areas of the 
body, such as lymph nodes, lungs, liver, brain or bone. 
Though often curable in its early stages, metastatic 
malignant melanoma is an extremely aggressive can-
cer with no current viable treatment. Thus, any suc-
cessful treatment for melanoma has to target metas-
tasis. Invasion of host tissues by cancer cells requires 
alteration of cancer cell adhesion, cell migration and 
proteolytic degradation of the extracellular matrix 
(ECM) [1]. Stromal resistance is dependent upon the 
ability of the host to encapsulate tumor cells in a dense 
barrier of fibrous tissue. Rath and Pauling postulated 
that essential nutrients needed for optimum synthesis 
and structure of collagen, such as vitamin C and lysine 
are critical components in natural control of spread 
and invasion of cancer cells in the body [2]. Ascorbic 
acid, needed for synthesis and hydroxylation of col-
lagen and optimal stability of the extracellular matrix 
(ECM), is internally produced by most animals but not 
by humans [2]. Humans must obtain ascorbate by diet 
and cancer patients have been shown to have very low 
reserves of vitamin C [3, 4]. 
Dr. McCormick was the first to note that the gen-
eralized stromal changes of scurvy were identical with 
the local stromal changes observed in cancer in the im-
mediate vicinity of invading neoplastic cells [5]. Scurvy, 
which results from severe dietary lack of ascorbate, 
is characterized by generalized tissue disintegration, 
including the intercellular ground substance and the 
collagen bundles, and lysis of the interepithelial and 
interendothelial cements. This condition leads to ul-
ceration, secondary bacterial infection, vascular dis-
organization (edema and interstitial hemorrhage) and 
generalized cellular proliferation, with specialized cells 
through the tissue reverting to a primitive form. Pa-
tients with advanced cancer exhibit symptoms virtually 
identical with those shown by humans with advanced 
scurvy: anemia, cachexia, extreme lassitude, hemor-
rhages, ulceration, susceptibility to infections and 
abnormally low tissue, plasma and leukocyte ascor-
bate levels, and terminal adrenal failure. Suggestions 
have been proposed to supplement cancer patients 
with ascorbate to reverse their scorbutic symptoms 
and treat the cancer, as well as improve the patients’ 
quality of life [6, 7].
Our main objective was to determine the effect 
of ascorbate supplementation in mice unable to syn-
thesize ascorbic acid, gulonolactone oxidase (gulo) 
knockout (KO) mice, on the development of tumors 
when challenged with murine B16FO cancer cells.
METHODS AND MATERIALS
Animals. Female Balb/C wild type mice and mice 
heterozygous for the sfx mutation, a deletion in the L-
gulono-gamma lactone oxidase gene (gulo) were ob-
tained from The Jackson Laboratory (Bar Harbor, ME). 
The gulo mice were bred to develop a homozygous 
gulo (-/-) colony and were maintained on Vitamin C for-
tified food and water. Genotyping of litters was per-
formed through Transnetyx (Cordova, TN) and female 
gulo (-/-) mice were selected from the homozygous 
colony for the study. Wild type and gulo (-/-) mice se-
lected for the study were approximately 36–40 weeks 
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of age. They were acclimated for a week before 
treatments, housed in standard separator cages with 
bedding on a 24-hour light/dark schedule. All animals 
were cared for in accordance with institutional guide-
lines for the care and use of experimental animals. 
 Diet. Gulo (-/-) mice were divided into two groups: 
group 1 (n = 11) and 2 (n = 11) and wild type mice 
(n = 6) were allocated to group 3. Prior to injection with 
melanoma cells, the groups of mice were maintained 
for 4 weeks on the following diets. Group 1 (vitamin 
C deprived gulo (-/-) mice) and Group 3 (wild type 
mice) were maintained on a regular diet (Laboratory 
Rodent Diet 5001 from Purina Mills, LLC/Test Diet) 
and distilled water.  Group 2 (vitamin C-supplemented 
gulo (-/-) mice) were provided the regular diet supple-
mented with 500 ppm L-ascorbyl-2-polyphosphate 
and distilled water with 150 mg/L ascorbic acid, 
0.01 mM EDTA. The ascorbate-supplemented nutrient 
mix diet was milled and pressed by Purina Mills, LLC. 
Experimental design. After mice had been 
on their respective diets for 4 weeks, 2.5 × 106 murine 
melanoma B16FO cells in 0.2 ml PBS and 0.1 ml Matri-
gel (BD Bioscience, Bedford, MA) were injected 
subcutaneously into the shaven right flank of each 
mouse. Mice were continued on their respective di-
ets for another 2 weeks. Body weight measurements 
(in triplicates) of all mice were taken every 3 to 4 days 
beginning 1 week before harvest. The mice were then 
sacrificed, blood was drawn and their tumors were 
measured, excised, weighed, photographed and pro-
cessed for histology. All procedures were conducted 
under protocols approved by the Internal Animal Care 
and Use Committee (IACUC).
Serum analysis. Serum was processed from 
whole blood and stored at -80°C until analyzed. Cy-
tokine analyses, including interleukin (IL)-6, IL-1β, 
granulocyte macrophage colony-stimulating factor 
(GM-CSF), tumor necrosis factor (TNFα), IL-2 and 
vascular endothelial growth factor (VEGF), were run 
in duplicates by Procarta® Cytokine Assay Service us-
ing Procarta® Cytokine kit mouse 8-plex at Affymetrix 
(Santa Clara, CA). Serum ascorbate analysis was per-
formed using the Ferric Reducing Ascorbate (FRASC) 
Assay Kit form Biovision (Mountain View, CA).
Histology. Tumors were placed in a formalin cas-
sette and sent to IDEXX for analysis. Formalin fixed 
samples of tumors, skin, kidneys and livers were 
trimmed, processed, blocked, sectioned and stained 
with H&E and EVG stains, and evaluated microscopi-
cally by IDEXX Pathology.
Statistical analysis. The results were expressed 
as means ± SD, as indicated in the results, for the 
groups. Data was analyzed by independent sample “t” 
test using MedCalc Software (Markakerke, Belgium).
RESULTS
Effect of dietary ascorbate on tumor growth 
in mice. The mean tumor weight in ascorbate supple-
mented mice (0.114 ± 0.096 g) was significantly re-
duced (by 64%, p = 0.004 ) compared to tumor weight 
in ascorbate-deprived gulo KO mice (0.317 ±  0.155 g), 
as shown in Fig. 1. The mean tumor weight of wild type 
mice (0.109 ± 0.064 g) was not statistically significant 
from the ascorbate-supplemented mice. Among 
the gulo (-/-) mice deprived of ascorbate two mice 
developed metastasis and one a premature death, 
while neither the wild type nor ascorbate supple-
mented gulo (-/-) mice developed metastases. Gross 
tumor photographs of representative tumors from the 
gulo KO groups is shown in Fig. 2. (Note: Among the 
supplemented group, 3 data points were removed due 
to 2 gravidities and 1 anesthesia death before tumor 
inoculation).
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Fig. 1. Effect of ascorbate on B16FO melanoma growth in gulo 
KO mice (SEM bars)
Fig. 2. Effect of ascorbate on B16FO melanoma growth in gulo 
KO mice: gross tumor photographs of groups
Effect of vitamin C supplementation on tumor 
histology. Gulo KO mice supplemented with ascor-
bate hosted smaller tumors with more collagen en-
capsulation and fibrous capsule interdigitation (Fig. 3, 
a). The smallest tumor had an unusually thick fibrous 
capsule of collagen and a few elastic fibers. In contrast, 
gulo KO mice deprived of ascorbate hosted large 
tumors with poorly defined borders, showing more 
necrosis and mitosis (Fig. 3, b). These conditions co-
incided with severe metastasis from the primary tumor 
to the colon and/or spleen in a couple of the ascorbate 
deprived gulo KO mice (a more dynamic tumor charac-
terized by cell death and turnover and poorly defined 
borders correlates with metastasis). Wild type mice 
challenged with melanoma cells formed well-defined 
tumors, encapsulated with a fibrous capsule of colla-
gen. An inflammatory infiltrate was observed in some 
wild type tumors.
Effect of dietary ascorbate on weight of mice. 
The mean weight of mice in each group did not sig-
nificantly differ at onset or at 7 days post injection. 
However, the mean weight of ascorbate restricted gulo 
(-/-) mice significantly decreased with time, showing 
a 30% (p < 0.0001) decrease in weight at 14 days 
post injection compared to the mean weight at 7 days 
post injection. Furthermore, the weight of ascorbate-
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supplemented gulo (-/-) mice continued to increase 
slightly over time, but did not reach statistical signifi-
cance. However, the final mean weight of gulo (-/-) 
ascorbate-deprived mice was 36% lower than the 
mean final weight of gulo (-/-) mice supplemented 
with ascorbate, as shown in Fig. 4.
a
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Fig. 3. Effect of ascorbate on B16FO melanoma tumors in gulo 
KO mice: representative histology of tumors in the gulo KO mice 
groups. a — ascorbate-supplemented gulo KO mice showing 
strong tumor capsules (pink); b — scorbutic gulo KO mice show-
ing weak or absent tumor capsules
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Fig. 4. Effect of ascorbate on animal weights (in g ± SD) in mela-
noma bearing mice: comparison of the mean weights of wild 
type and gulo (-/-) ascorbate depleted and supplemented 
mouse groups
Effect of ascorbate supplementation on cyto-
kines. Serum inflammatory cytokines IL-6 and IL-1β 
were substantially higher in gulo KO mice deprived 
of ascorbate than in gulo KO mice supplemented with 
ascorbate, as shown in Fig. 6. For the gulo KO scorbu-
tic mouse group, the mean IL-6 level per mouse was 
6.97 ± 7.85 pg/mL compared to  0.715 ± 1.08 in the 
ascorbate supplemented gulo KO group (90% de-
crease, p = 0.04). In regard to IL-1β, ascorbate supple-
mentation resulted in a 62% decrease from the level 
in the restricted gulo KO group, but the difference did 
not reach statistical significance. Mean IL-1β levels per 
mouse were 2.82 ± 5.68 and 7.25 ± 6.74 pg/mL in the 
ascorbate supplemented and deprived gulo KO mice, 
respectively. The mean IL-1β level in wild type mice was 
significantly lower (11%, p = 0.04) than in the ascor-
bate deprived gulo KO mice but did not significantly 
differ from the mean level in ascorbate supplemented 
gulo KO mice. Mean GM-CSF, TNFα, IL-2 and VEGF 
levels did not significantly differ between ascorbate 
supplemented and deprived gulo KO mice. See Table 
and Fig. 5 for cytokine levels in groups.
Table. Mean serum cytokine levels (pg/mL ± SD) in melanoma bearing mice
Cytokine Wild Type (Control) GULO KO — Ascorbate GULO KO + Ascorbate
IL-1β 0.772 ± 1.89 7.25 ± 6,74 2.82 ± 5.68
IL-6 0.592 ± 0.292 6.97 ± 7.84 0.715 ± 1.08
GM-CSF 2.31 ± 2.67 6.76 ± 4.71 8.95 ± 13.6
TNF-α 2.31 ± 2.50 2.07 ± 0.962 2.38 ± 2.79
IL-2 0.607 ± 0.181 0.641 ± 0.144 0.65 ±0.265
VEGF 17.8 ±8.85 13.8 ± 7.01 17.0 ± 8.59
Notes: IL-1β — interleukin-1β, IL-6 — interleukin-6, GM-CSF — granulocyte 
macrophage colony-stimulating factor, TNF-α — tumor necrosis factor-α, 
IL-2 — interleukin-2, VEGF — vascular endothelial growth factor.
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Fig. 5. Comparative mean serum cytokine levels in melanoma 
bearing groups of mice
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Fig. 6. Effect of ascorbate supplementation on mean IL-6 and 
IL-1β levels in gulo KO mice (using SEM bars)
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Effect of ascorbate supplementation on serum 
ascorbate levels in gulo KO mice. As expected, 
ascorbate-supplemented gulo KO mice were found 
to have profoundly higher ascorbate levels than did the 
unsupplemented gulo KO mice (Fig. 7). Mean serum 
ascorbate level in ascorbate restricted mice (7.72 ± 
15.5 µM) was 9% (p < 0.001) of the mean ascorbate 
level in supplemented mice (85.8 ± 22.6 µM). Wild type 
mice also showed significantly higher ascorbate levels 
than the restricted mice (68.6 ± 17.1 µM). The mean 
ascorbate level in wild type mice was found to be 80% 
of that in ascorbate supplemented mice, but the dif-
ference did not reach statistical significance.
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Fig. 7. Comparative mean serum ascorbate levels in groups 
of melanoma bearing mice (using SEM bars)
DISCUSSION
Numerous studies report that cancer patients 
exhibit abnormally low plasma ascorbate levels sec-
ondary to the disease and/or treatment [3, 4, 8, 9]. 
Studies have demonstrated a correlation between de-
ficient plasma ascorbate levels in cancer patients and 
decreased survival, as well as increased expression 
of inflammatory markers [8]. A correlation between 
tumor aggressiveness and low ascorbate content has 
also been reported [9]. Ascorbate has been implicated 
in host resistance to neoplasia, at both the stromal 
and systemic levels. Invasiveness, characteristic 
of melanoma and other metastatic cancers, depends 
upon the structural integrity of the ground substance 
matrix as a barrier to invasiveness. Degradation of ad-
jacent matrix in the vicinity of invading neoplastic cells 
is dependent upon continual release of lysosomal 
glycosidases (hyaluronidases) [6], proteases and 
collagenases from the invading cells [1, 10]. 
In our study, ascorbate supplementation of gulo 
KO mice resulted in significant reduction (by 64%, 
p = 0.004) in the mean tumor weight compared to that 
in ascorbate-deprived gulo KO mice, In addition,  gulo 
KO mice supplemented with ascorbate hosted smaller 
tumors with enhanced collagen encapsulation and fi-
brous capsule interdigitation. In contrast, gulo KO mice 
deprived of ascorbate hosted large tumors with poorly 
defined borders, showing more necrosis and mitosis. 
Tumors in scorbutic mice with systemic metastasis 
showed multi-focal collagen capsule breaks or absent 
collagen capsules. Tumors in ascorbate supplemented 
gulo KO mice had much thicker collagen capsules 
and were of similar size to those in wild type vitamin 
C generating mice.
Interestingly, Moriarty et al. [11] reported that 
a shift of ascorbate occurs from reserves to the tu-
mor stroma, resulting in ascorbate levels in human 
tumors to be higher than that in the surrounding tis-
sues, resulting in significant depletion of circulating 
reserves. The ascorbate is reported to concentrate 
at the periphery of the tumor, against the actively 
growing invasive margin [12]. Although most animals 
can synthesize ascorbic acid, humans cannot and are 
totally dependent upon dietary intake. Ascorbic acid 
is known to be required for the structural integrity of the 
intercellular matrix and closely related to glucoronic 
acid, an essential building block of the matrix structure. 
Increasing amounts of ascorbic acid are needed for 
protective encapsulation of tumors. Stromal resistance 
is dependent upon the host’s ability to encapsulate the 
neoplastic cells by forming a practically impenetrable 
barrier of dense fibrous tissue [6]. Highly anaplastic 
invasive tumors are associated with a scanty, poorly 
defined collagenous barrier. Collagenous barriers 
are found to be more defined in tumors of moderate 
rapidity of growth and very abundant in slow-growing 
“contained” atrophic scirrhous tumors [6]. Our studies 
have shown that a combination of ascorbate with other 
micronutrients have profound anti-cancer effects 
mediated through increased stability of connective 
tissue, including suppression of metastasis, tumor 
growth, angiogenesis in more than 40 types of human 
tumor cells [13].
Cancer patients exhibit chronic low-grade inflam-
mation that causes a variety of pathologies, such 
as cachexia and poor postsurgical outcome [14, 15]. 
Levels of serum cytokines, such as IL-6, IL-1β, IL-1α, 
IL-8, IL-12p40 IL-13, GM-CSF, monocyte chemoat-
tractant protein- (MCP-1), macrophage inflammatory 
protein (MP)-1α, MP-1β, IFNα, tumor necrosis factor 
(TNF)-α, epidermal growth factor, VEGF and TNF re-
ceptor II are reported to be significantly higher in pa-
tients with resected high-risk melanoma than in healthy 
controls [16]. These factors promote tumor cell growth 
and stimulate endothelial cell proliferation, migration 
and angiogenesis, which lead to melanoma growth 
and metastasis [17]. Clinical studies have shown sig-
nificantly increased levels of serum IL-6 in malignant 
metastatic melanoma patients and have been found 
to be correlated to the tumor burden in these patients 
[18–20]. Since IL-6 promotes melanoma progression 
and resistance to chemotherapy, new approaches 
to treatment have focused on targeting IL-6. In our 
study, ascorbate supplementation of scorbutic mice, 
showed significantly reduced levels of IL-6 than the 
ascorbate deprived scorbutic mice. Of interest, weight 
loss occurred in the gulo (-/-) mice deprived of ascor-
bate but not in those supplemented with ascorbate. 
The weight loss observed in cancer patients, second-
ary to the inflammation-associated cachexia, mirrors 
the weight loss observed in the scorbutic mice with 
high IL-6 and IL-1β levels. 
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The comparative ascorbate serum levels in the 
respective groups of mice support the claim that the 
beneficial effects observed in the ascorbate-supple-
mented mice were due to significantly increased serum 
ascorbate levels. Among the melanoma bearing mice 
in this study, ascorbate-supplemented gulo KO mice 
were found to have profoundly higher (an increase 
of 1111%) ascorbate levels than did the restricted gulo 
KO mice and slightly higher (125%) levels than the 
ascorbate producing wild type mice.
In conclusion, ascorbate supplementation resulted 
in decreased tumor growth and enhanced encapsula-
tion of tumors elicited by melanoma challenge in scor-
butic mice. Tumor encapsulation is critical in curbing 
invasion and metastasis of malignant cells. In addition, 
ascorbate supplementation modulated inflammatory 
cytokine secretion.
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